Co-adjuvant nano particles for hepatocellular carcinoma radiotherapy treatment.

IF 2.1 Q3 ONCOLOGY
Ramy Sabry Abd-Elsamee, Doaa Ezzat Sayed Ahmed, Khalid Shaaban Hashem, Ahmed Nabil
{"title":"Co-adjuvant nano particles for hepatocellular carcinoma radiotherapy treatment.","authors":"Ramy Sabry Abd-Elsamee, Doaa Ezzat Sayed Ahmed, Khalid Shaaban Hashem, Ahmed Nabil","doi":"10.1186/s43046-025-00300-3","DOIUrl":null,"url":null,"abstract":"<p><p>HCC is one of the most life-threatening human cancers in the world. It is considered the major malignant tumor of the liver in adults and is the most common cause of death in people with cirrhosis. Chemotherapy is widely used for HCC treatment, but it has many side effects. Therefore, an alternative, safe method with low side effects, low toxicity, and a higher anti-cancer effect is in demand. In our study, we used Se-NPS alone and combined it with Gamma and UV radiation at different doses. We also used the chemotherapeutic drug sorafenib on Hep G2 cell lines to compare the effect of Se-NPS (with and without radiation) with the sorafenib group. Our results showed that Selenium alone without radiation had a lesser effect on eliminating cancer cells, with high cell viability and fewer apoptotic effects. On the other hand, Selenium combined with radiation, especially at high doses of UV (180 s) and gamma (0.2 Gy), had the highest effect on killing cancer cells. This combination resulted in significantly lower cell viability, high DNA fragmentation, and a high apoptotic effect due to a significant elevation of P53 and cytosolic cytochrome C, which was better than the Radiation-only groups.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"50"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-025-00300-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

HCC is one of the most life-threatening human cancers in the world. It is considered the major malignant tumor of the liver in adults and is the most common cause of death in people with cirrhosis. Chemotherapy is widely used for HCC treatment, but it has many side effects. Therefore, an alternative, safe method with low side effects, low toxicity, and a higher anti-cancer effect is in demand. In our study, we used Se-NPS alone and combined it with Gamma and UV radiation at different doses. We also used the chemotherapeutic drug sorafenib on Hep G2 cell lines to compare the effect of Se-NPS (with and without radiation) with the sorafenib group. Our results showed that Selenium alone without radiation had a lesser effect on eliminating cancer cells, with high cell viability and fewer apoptotic effects. On the other hand, Selenium combined with radiation, especially at high doses of UV (180 s) and gamma (0.2 Gy), had the highest effect on killing cancer cells. This combination resulted in significantly lower cell viability, high DNA fragmentation, and a high apoptotic effect due to a significant elevation of P53 and cytosolic cytochrome C, which was better than the Radiation-only groups.

纳米粒子辅助肝癌放射治疗。
HCC是世界上最危及生命的人类癌症之一。它被认为是成人肝脏的主要恶性肿瘤,是肝硬化患者最常见的死亡原因。化疗被广泛用于肝细胞癌治疗,但它有许多副作用。因此,需要一种副作用小、毒性低、抗癌效果高的安全替代方法。在我们的研究中,我们单独使用Se-NPS,并结合不同剂量的伽马和紫外线辐射。我们还使用化疗药物索拉非尼对Hep G2细胞系进行比较Se-NPS(有和没有放疗)与索拉非尼组的效果。我们的研究结果表明,单独使用硒而不使用辐射对癌细胞的清除作用较小,细胞活力高,凋亡作用较小。另一方面,硒与辐射结合,特别是在高剂量紫外线(180 s)和伽马(0.2 Gy)下,对癌细胞的杀伤效果最高。这种组合导致细胞活力明显降低,DNA片段化程度高,由于P53和细胞质细胞色素C的显著升高,导致细胞凋亡效应高,这比单纯放疗组要好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信